Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 7/20 | 0.38 |
| ▸ | HTR2A | P28223 | 7/20 | 0.38 |
| ▸ | HTR6 | P50406 | 7/20 | 0.38 |
| ▸ | HTR7 | P34969 | 6/20 | 0.38 |
| ▸ | HTR1A | P08908 | 6/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18876494 | 0.85 | LRRK2 (0.37) | MAPTLRRK2KDM4EALDH1A1FFAR4 | |
| SCHEMBL18876365 | 0.85 | MAPT (0.39) | MAPTLRRK2KDM4EALDH1A1FFAR4 | |
| SCHEMBL17432215 | 0.82 | ALDH1A1 (0.46) | MAPTLRRK2ALDH1A1 | |
| SCHEMBL14922715 | 0.81 | CCR4 (0.46) | MAPTDRD2KDM4EL3MBTL1MEN1 | |
| Hydrochloric Acid SCHEMBL17422193 | 0.81 | ALDH1A1 (0.49) | MAPTLRRK2KDM4EALDH1A1 | |
| SCHEMBL25493021 | 0.78 | FFAR4 (0.51) | MAPTDRD2HTR2AHTR6HTR7 | |
| SCHEMBL14924079 | 0.77 | MAPT (0.42) | MAPTKDM4EALDH1A1L3MBTL1KMT2A | |
| SCHEMBL25493024 | 0.77 | HTR3A (0.47) | MAPTLRRK2KDM4EALDH1A1TDP1 | |
| SCHEMBL17432259 | 0.77 | MEN1 (0.36) | MAPTDRD2HTR2AHTR6HTR7 | |
| SCHEMBL17432266 | 0.77 | MAPT (0.40) | MAPTDRD2HTR2AHTR6HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914737-B2 | Triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | ST PHARM CO., LTD. (KR) | 2018-03-13 | — | — | US | disclosed |
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | TNKS1BP1, TNKS, TPI1 | MAPT 44/4885DRD2 4637/4885HTR2A 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.